CD4
؉ N atural killer T cells are a specialized subset of the T cells which are important regulators of several immune responses (1) (2) (3) . NKT cells are special in that they express T cell (such as ␣␤ TCR) and NK-lineage (e.g., CD161 (NK1.1), CD16, Ly49A, and Ly49C) cell surface markers and key cytokines (e.g., IL-4 and IFN-␥) which regulate the course of the immune response. NKT cells secrete large quantities of IL-4 after activation, both in vitro and in vivo (4, 5) , and it has been theorized that they also direct the immune response toward a Th2 phenotype (6) . NKT cells have also been demonstrated to generate the Th1 cytokine, IFN-␥, after activation via NK1.1 (7) or TCR engagement (8) , and have been determined to display Th0 cytokine profiles with both IFN-␥ and IL-4 (9) . The majority of these T cells have also been shown to express highly restricted TCRs, comprised of an invariant V␣14-J␣18 TCR ␣-chain in association with a repertoire of V␤8, V␤7, or V␤2 gene products (10) . NKT cells exhibit the characteristics of activated memory cells, and also evidence autoreactivity in the absence of prior exposure to Ags. Thymic selection and development in NKT cells is restricted by CD1d, which is well-conserved throughout mammalian species. CD1d is nonpolymorphic as compared with conventional MHC I molecules and presents lipid/glycolipid Ags to NKT cells (10) . The nonpolymorphic nature of the Ag-presenting CD1d, coupled with their restricted TCR repertoire, their prompt secretion of a variety of key cytokines, and their intrinsic memory phenotype, renders NKT cells excellent candidates for innate immune-regulatory cells.
The synthetic glycolipid, ␣-galactosylceramide (␣-GalCer), 3 a CD1d ligand, is a profound stimulator which is able to activate NKT cells, rendering it a powerful candidate for adjuvant therapy (11) . It has been recently reported that ␣-GalCer induces dendritic cell (DC) maturation, effecting an integration of the innate immune response with the appropriate adaptive response. This conclusion was predicated on the observation that the treatment of soluble Ag in the presence ␣-GalCer-mediated NKT cell stimulation enhances CD4 ϩ and CD8 ϩ T cell responses via DC maturation (12) (13) (14) . Gonzalez-Aseguinolaza et al. (15) previously reported that the coadministration of ␣-GalCer with a malaria Ag augments protective antimalaria immunity in mice. Although they used OVA or malaria Ag, both of which exhibit comparatively high antigenicity, the results of that study suggested that ␣-GalCer functions as a powerful, immune response-enhancing adjuvant. We reported in a previous study that ␣-GalCer can also function as an intranasal vaccine adjuvant (16) . As this glycolipid appears to lack toxicity in humans, it may also prove to be useful in vaccine and pharmaceutical therapy design (17) .
Although the antitumor effects of NKT cells, and their ligand ␣-GalCer, have been relatively well-documented, the relative contributions and importance of CD4 ϩ and CD8 ϩ T cells in the immunization and adaptive phases have yet to be clearly defined. On the basis of the distinctive features of NKT cells and ␣-GalCer, we elected to evaluate the ␣-GalCer-mediated mechanism that augments protective immune response during the adaptive phase, using whole-tumor Ags. NKT cells, MHC class II-restricted CD4 ϩ T cells, and the IFN-␥ generated by the activated CD4 ϩ T cells were all found to be critical with regard to the enhancement of the adaptive immune response against low-antigenicity tumor Ags. Surprisingly, MHC class I-restricted CD8 ϩ T cells, which are commonly believed to function as the dominant effector cells that mediate tumor killing (18) , were found to be dispensable in the mediation of antitumor adaptive immunity. Moreover, CD8 ϩ T cell deficiency augmented both antitumor immune response and the survival of tumor-challenged animals in an ␣-GalCer-immunized model.
Collectively, our data demonstrate that IFN-␥, NK cells, and Th1-type CD4 ϩ T cells are crucial to tumor rejection. Our findings imply that activated NKT cells may induce a powerful adaptive immune response, operating via CD4 ϩ T cells, against Ags with very low antigenicity, including tumor extracts.
Materials and Methods

Mice and cell lines
, and TNFR-deficient mice (TNFR Ϫ/Ϫ ), all in the B6 background, were purchased from The Jackson Laboratory. The BALB/c mice were purchased from Charles River Laboratories. Mice deficient of K b D b (referred to as MHC class I deficient), I-A b (MHC class II deficient), and CD1d (CD1d1/CD1d2 deficient) were used after Ͼ12 backcrosses to B6 (19, 20) . All results reported in this study were derived from comparative analyses of littermates expressing Ϫ/Ϫ vs ϩ/Ϫ or ϩ/ϩ genotypes. All mice were raised in a specific pathogen-free environment at Korea University, and used at 7-10 wk of age, unless otherwise specified. The experimental protocols adopted in this study were consistent with the rules established by the Korean Animal Protection Law, and all protocols were approved by the Laboratory Animal Care and Use Committee of the College of Life Sciences and Biotechnology (Korea University). B16 and EL-4 (all H-2 b ) cells were acquired from the American Type Culture Collection (ATCC). The 26-M3.1 colon cells (H-2 d ) used in the study was a gift from Dr. T. J. Yoon (Kyonggi University, Suwon, Korea). MB19 (H-2 b ), a methylcholanthrene (purchased from Sigma-Aldrich)-induced fibrosarcoma, was derived from mice injected with 100 g of methylcholanthrene. All cell lines were maintained in RPMI 1640 complete medium (Invitrogen Life Technologies) supplemented with 10% heat-inactivated FBS (HyClone), 2 mM L-glutamine, 50 U/ml penicillin, 50 g/ml streptomycin, 10 g/ml gentamicin sulfate, and 5 M 2-ME (all from Invitrogen Life Technologies).
␣-GalCer, CFA, and tumor Ag
-octadecanetriol] used in this study was a gift from Dr. A. Bendelac (Chicago University, Chicago, IL). It was dissolved in 0.5% polysorbate-20 (Nikko Chemical) in 0.9% NaCl solution, and diluted with PBS before use. CFA (Mycobacterium tuberculosis) was purchased from Sigma-Aldrich. The tumor Ags were prepared via more than three freeze/thaw cycles or by the gamma-irradiation (30 Gy) of tumor cells. The tumor Ags were diluted in PBS equivalent to 1 ϫ 10 7 cells/ml, and were cryopreserved at a temperature of Ϫ70°C.
Vaccinations and tumor models
Mice were immunized i.p. with 100 l of tumor Ag, at a level equivalent to 5 ϫ 10 5 tumor cells. Vehicle (Veh) or 1 g of ␣-GalCer was coadministered with the tumor Ag when required. The immunization schedules are described in detail in the figure legends. Two weeks after immunization, 1 ϫ 10 5 live tumor cells were injected i.p., s.c., or i.v. In the i.p. tumor model mice, survival was monitored for up to 9 wk. In the s.c. tumor model mice, tumor weight at the site of inoculation was measured 3 wk after tumor injection. In the i.v. tumor model mice, each group was sacrificed 3 wk after tumor injection, and the lung foci (visible as black spots) were counted.
Collection and preparation of lymphocytes
The peritoneal cells were collected via two peritoneal cavity washes (PBS) of the tumor-bearing vaccinated mice. The cells were washed two additional times with PBS before their use in the in vitro assays.
The spleen and liver were removed from the vaccinated mice 1, 4, or 7 days after tumor challenge, minced, passed through a nylon mesh, and suspended in PBS. The erythrocytes were lysed in 150 mM ammonium chloride lysis buffer (ACK). The remaining cells were then suspended in PBS, centrifuged over a layer of Lympholyte-M (Cedarlane Laboratories) at 2000 rpm at room temperature for 20 min, and the lymphocytes were collected at the interface between the Lympholyte and PBS.
Cytotoxic assay ([ 3 H]thymidine assay)
For the assay against tumor Ag, the mice were immunized with tumor Ag, coupled with either ␣-GalCer or Veh. Spleen cells were restimulated in vitro with 20 U/ml recombinant human IL-2 (PeproTech) plus tumor Ag for 5 days, after they were obtained at 14 days after immunization. (21, 22) . After 6 h of incubation at 37°C in a humidified, 5% CO 2 atmosphere, the plates were freezethawed three times, harvested, then measured using a micro-beta counter (Wallac). The percentage of specific lysis was calculated in triplicate, as follows: percent-specific lysis ϭ ((cpm spontaneous value Ϫ cpm experimental value)/cpm spontaneous value) ϫ 100.
Flow cytometric (FACS) analysis and mAbs
Cells were stained in FACS staining buffer (PBS containing 0.1% BSA and 0.01% sodium azide), incubated for 20 min at 4°C with anti-FcR-␥ mAb 2.4G2, then labeled for 30 min with the appropriate mAb conjugated to biotin (bio), FITC, R-PE, CyChrome, or allophycocyanin. When the mAbs were biotinylated, streptavidin (StAv)-PE or StAvallophycocyanin was used as a second-step reagent. ␣-GalCer/CD1d-tetramers were produced and used for staining as described previously (23, 24 
Intracellular cytokine production analyses
Tumor cells (1 ϫ 10 5 ) were i.p. inoculated into the immunized mice. One, 4, or 7 days later, single-cell suspensions of peritoneal cells from the tumor-injected mice were prepared as described above, and cultured for 6 h with Golgi stop (BD Pharmingen) in RPMI 1640 culture medium. To determine the intracellular cytokine levels, the cells were initially stained with the appropriate mAb, fixed and permeabilized with Cytofix/Cytoperm solution (BD Pharmingen), and finally stained with allophycocyanin-conjugated anti-IL-4, anti-IL-12, and anti-IFN-␥ mAbs for 45 min on ice. The percentages of cells expressing cytoplasmic IL-4, IL-12, and IFN-␥ were determined via flow cytometry (FACSCalibur). IFN-␥ and IL-4 concentrations were measured using an enzyme-linked immunoassay kit (OPTEIA Mouse IFN-␥ and IL-4 set; BD Pharmingen), on the basis of a standard curve for recombinant mouse IFN-␥ and IL-4.
In vivo depletion of CD8 ϩ T cells and DC transfer
For the in vivo depletion of CD8 ϩ T cells, mice were injected with 250 g of cytotoxic anti-CD8 mAb 2.43 (rat IgG2b). The mice were administered two i.p. injections on 3 days and 1 day before immunization or to tumor challenge. The control mice received 250 g of rat IgG. This depletion was previously determined to be sufficient for the depletion of all CD8 ϩ cells in mice (as determined via flow cytometry). For the transfer of the DCs, the DCs were obtained from naive mice spleens via MACS using magnetic bead-conjugated anti-CD11c mAb, bio-conjugated anti-CD8 mAb, and StAv-conjugated magnetic beads (Miltenyi Biotec), in accordance with the manufacturer's instructions. The DCs were injected i.p. into naive mice on the day of the tumor challenge.
Statistical analysis
Student's t tests were used to determine statistically significant differences between the two groups. Log-rank tests were used to analyze the mouse survival curves. Throughout the text, figures, and legends, the following terminology was used to denote statistical significance: ‫,ءءء‬ p Ͻ 0.0001 or p Ͻ 0.001; ‫,ءء‬ p Ͻ 0.01; ‫,ء‬ p Ͻ 0.05.
Results
NKT cells promote an Ag-specific adaptive immune response
It has been demonstrated that the coadministration of ␣-GalCer with a malaria Ag augments the level of protective antimalarial adaptive immunity (15) . Several previous reports have indicated that ␣-GalCer-mediated NKT cell activation induces an antitumor immune response (14, 25) . To assess the adjuvant activity of ␣-GalCer for tumor Ags, we immunized mice with tumor extracts. B6 mice immunized with B16 whole tumor extract (10 3 -10 7 cells/ mouse) alone evidenced no protective immune response against the live B16 tumor cells 2 wk after immunization (data not shown). Tumor extract immunized with CFA was associated with a marginally increased survival time, but did not result in complete protection. However, mice treated with ␣-GalCer at the time of the immunization with tumor Ag evidenced substantially enhanced survival as compared with what was seen with CFA, whereas the Veh-treated control mice demonstrated no such enhanced survival effects (Fig. 1A ). This effect was determined to have been mediated by NKT cells, as only the littermate control heterozygotic (He, CD1d ϩ/Ϫ ) mice, and not the NKT cell-deficient CD1d Ϫ/Ϫ mice, were protected by this immunization. Furthermore, mice immunized 150 days before tumor challenge retained their antitumor immune response characteristics. These findings demonstrated that the activation of NKT cells at the time of tumor vaccination successfully established long-term memory cells against B16 tumors (Fig. 1A) . 
Vaccination with ␣-GalCer induces effective antitumor immunity regardless of the mouse strain, tumor type, or tumor site
We attempted to determine whether the adjuvant effects of ␣-GalCer were applicable to other tumor cell lines and tumor injection tissues in different mouse strains. First, we immunized BALB/c CD1d Ϫ/Ϫ mice and littermate CD1d ϩ/Ϫ mice with extracts of the 26-M3.1 colon cancer cell line. We then coadministered either ␣-GalCer or Veh, and initiated a challenge with live tumor cells 2 wk later. Only the CD1d ϩ/Ϫ mice who had been administered ␣-GalCer were protected (Fig. 1B) . To evaluate the protective effects of ␣-GalCer against different tumor lines, we immunized B6 mice with the extract of the lymphoma cell line, EL-4 (Fig. 1C) , or the sarcoma cell line, MB19 (Fig. 1D) . Only CD1d ϩ/Ϫ mice that had been immunized with the Ag in the presence of ␣-GalCer were found to be protected against the live tumor challenge. All other groups, including the group of CD1d Ϫ/Ϫ mice immunized with Ag coupled with ␣-GalCer, were not protected. These findings clearly show that the adjuvant effects of ␣-GalCer occur independently of the mouse strain and the tumor type.
We also attempted to determine whether enhanced immunization with ␣-GalCer would affect the rejection of tumor cells injected into different anatomical sites. Rather than administering i.p. injections, ␣-GalCer and tumor Ag were immunized into He and CD1d Ϫ/Ϫ B6 mice either s.c. or i.v., into the left flank (Fig. 1E) or the tail vein (Fig.  1F) , respectively. Three weeks later, the tumor masses growing on the left flanks of the injected mice were excised and weighed. The tail vein-injected mice were sacrificed 3 wk after the challenge, and the metastatic lung tumor nodules were counted. In all cases, the CD1d ϩ/Ϫ mice immunized with tumor extract coupled with ␣-GalCer evidenced a controlled growth of the recently implanted tumor cells. Collectively, these data support the notion that ␣-GalCer exerts a profound and general adjuvant effect on antitumor response in a variety of mice strains, tumor lines, and tumor sites.
NKT cell activation enhances cytotoxic activity
NKT cells influence the quality of the adaptive immune response and augment cytotoxic activity (25) . Therefore, we attempted to determine whether vaccination with ␣-GalCer augmented cytotoxic capacity. Mice were immunized with B16 extract, in the presence of ␣-GalCer or Veh. Splenocytes and peritoneal cells were obtained 2 wk after immunization. The splenocytes of the CD1d ϩ/Ϫ mice immunized with ␣-GalCer evidenced an increase in cytotoxic activity against B16 (25% lysis with an E:T ratio of 10:1), as compared with the Veh-treated controls (25% lysis with an E:T ratio of 80:1, Fig. 2A, left panel) . The peritoneal cells of the CD1d ϩ/Ϫ mice that had been immunized with ␣-GalCer evidenced an increase in cytotoxic activity against B16 (40% lysis with an E:T ratio of 4:1) as compared with the Veh-treated controls (40% lysis with an E:T ratio of 50:1, Fig. 2A, right panel) . Whereas, enhanced-cytotoxic activity was not observed when splenocytes and peritoneal cells from MHCI Ϫ/Ϫ or MHCII Ϫ/Ϫ mice were used as effector cells (Fig. 2A) . Notably, peritoneal effector cells from CD4 ϩ T cell-deficient MHCII Ϫ/Ϫ mice showed minimal cytotoxic activity compare with Veh-control groups.
APC activation following tumor challenge is greatly enhanced in ␣-GalCer-immunized mice
Previous studies have reported that macrophages are recruited to tumor sites, where they function as effector or killer cells, facilitating the rejection of the tumor (26, 27) . Treatment with ␣-GalCer results in the full maturation of DCs, supporting the cytokines and presenting tumor Ags, thereby combining CD4 ϩ and CD8
ϩ T cell immunity against the relevant Ag (14, 28). To determine whether macrophages and DCs are activated and recruited to B16 tumor sites in an ␣-GalCer-immunized system, we isolated tumor-infiltrating immune cells from the peritoneal cavity at various time points (1, 4, and 7 days) after the injection of live tumor cells. The cells were then stained with Abs against macrophages (CD11b) and DCs (CD11c), and analyzed via flow cytometry. The CD11c ϩ cells reached Ͼ20% of all of the peritoneal cells in the ␣-GalCer-immunized He mice within 1 day, and this level was maintained until 4 days after challenge with B16 tumor cells. Significantly fewer DCs were observed in the B16 tumor sites of the Veh-immunized WT mice and ␣-GalCer-immunized CD1d Ϫ/Ϫ mice (Fig. 2B) . The CD11c ϩ cells also evidenced an activated phenotype, expressing higher levels of the costimulatory molecule, B7.2, in the spleen and peritoneal cavity cells of the WT mice immunized with ␣-GalCer, as compared with the mice that had been immunized with Veh (Fig. 2D) . Both the absolute number and percentage of macrophages/granulocytes (CD11b int -gated, Fig. 2C ) were increased soon after the injection of B16 tumor cells into the ␣-GalCerimmunized He mice, reaching their maximum level within 1 day. High levels, in this case, were maintained until day 4 (Fig.  2C) . Among the CD11b int cells, highly granulated cells were found to constitute ϳ21 and 40% of all of the CD11b int cells in the ␣-GalCer-immunized WT mice on days 1 and 4, respectively, but the same population in the Veh-immunized mice constituted only 5ϳ10% overall (data not shown). Highly granulated CD11b int (CD11b int SSC high ) cells expressed Gr-1, but not MHC class II, thereby indicating that the CD11b int SSC high cells were matured and differentiated granulocytes (data not shown). Activated CD11b int SSC low macrophages were also detected, which expressed higher levels of MHC II molecules and the costimulatory molecule B7.2 in the He mice immunized with ␣-GalCer than in the mice that had been immunized with Veh (data not shown). We additionally determined that the expression of the costimulatory molecule B7.2 was highly elevated in the peritoneal B cells of the ␣-GalCer-immunized WT mice, whereas the levels of B7.2 remained relatively unchanged in the splenic B cells (Fig. 2D) .
NK and CD4 ϩ T cells are the source of IFN-␥ for antitumor response
We assumed that Ag-specific CTLs would infiltrate and generate effector molecules, most notably IFN-␥, into the tumor inoculation site upon challenge with live tumor cells. Lymphocytes freshly isolated from the tumor challenge site were analyzed for the expression of IFN-␥, the prototypical Th1 cytokine, on days 1, 4, and 7 after tumor injection. We determined that CD4 ϩ CD8 Ϫ T cells from the He mice immunized with ␣-GalCer generated substantial amounts of IFN-␥ on day 1, which peaked on day 4 (Fig. 3A) . Unexpectedly, however, we were unable to detect a substantial population of IFN-␥-generating CD4 Ϫ CD8 ϩ T cells at any time point after the administration of tumor challenge (Fig. 3C) . By way of contrast, a significant portion of the NK cells were also determined to generate IFN-␥ on day 1, but with a slight decline, and an ultimate plateau occurring over the next 3 days (Fig. 3B) . However, neither the CD4 ϩ CD8 Ϫ T cells nor NK cells expressed any IFN-␥ in the vaccinated CD1d Ϫ/Ϫ mice or the Veh-treated He mice, thereby suggesting that the development of IFN-␥-producing CD4 ϩ T cells is dependent on CD1d molecules and NKT cell activation at the time of vaccination. To test the possibility that some IFN-␥-expressing CD4 ϩ T cells may be NKT cells, we measured IFN-␥ production of NKT cells after staining with ␣-GalCer/ CD1d-tetramer. CD4
ϩ NKT cells from ␣-GalCer-immunized mice significantly secreted IFN-␥ compared with the Veh control group only on day 1 (Fig. 3D) , indicating that NKT cells were also activated in early antitumor effector phase but constitute only a small part of IFN-␥-producing CD4 ϩ T cells.
MHC class II-dependent CD4 ϩ T cells are essentially required for NKT cell-dependent antitumor immunization, but MHC class I-dependent CD8 ϩ T cells are dispensable
To determine whether the activation of NKT cells at the time of immunization facilitates its effects via the promotion of the activation of a tumor Ag-specific conventional T cell population, we immunized both MHC class I-deficient (K bϪ/Ϫ D bϪ/Ϫ , marked as MHCI Ϫ/Ϫ ) and MHC class II-deficient (I-A bϪ/Ϫ , marked as MHCII Ϫ/Ϫ ) mice with a combination of ␣-GalCer and tumor extract, 2 wk before the administration of a B16 tumor challenge.
Surprisingly, the conventional CD8
ϩ T cell-deficient MHCI Ϫ/Ϫ mice evidenced potent tumor rejection and survival characteristics, comparable to those of WT mice. Similar results were also observed when different tumor cell lines (EL-4 and MB19) were challenged (Table I) . These data are consistent with the findings of Hung et al. (29) , who demonstrated that a significant fraction of CD8 Ϫ/Ϫ mice vaccinated with B16-GM-CSF also successfully rejected tumor tissue. However, CD4
ϩ T cell-deficient MHCII Ϫ/Ϫ mice were not protected by the same immunization protocol, and died 3 wk postinjection, in a manner similar to that observed with the CD1d Ϫ/Ϫ mice (Fig. 4A) . As the administered tumor Ag was prepared via a repeated freeze/thaw method, it is possible that the nature of the Ag induced the activation of a specific cell subpopulation. To address this question, we included tumor Ags prepared Table I shows the adjuvant effects of ␣-GalCer on protective antitumor immunity.
IFN-␥ is a key cytokine in NKT cell-mediated adaptive antitumor immunity
Both IFN-␥ and the lymphocytes perform crucial roles in the prevention of primary tumor development (30) in that they are both required during the early effector phase (31) . Therefore, we evaluated the effects of vaccination with ␣-GalCer on cytokine levels in serum (Fig. 5A ) and peritoneal lavage fluids (Fig. 5B) (Fig. 5C ).
The conventional CTL-independent antitumor immunity requires CD8
ϩ DCs
As the observed resistance of the MHCI Ϫ/Ϫ mice against tumor challenge was an unexpected result, we also attempted to evaluate this effect in mice in which the CD8 ϩ T cells had been depleted via the anti-CD8 Ab. We depleted the CD8 ϩ cells before immunization in a group of WT mice, and in another group of immunized WT mice, the CD8 ϩ cells were depleted immediately before the challenge with live tumor cells. Treatment with anti-CD8 Ab before immunization did not impair the survival of the immunized mice, as compared with the isotypematched control Ab-treated mice. However, the immunized mice to which anti-CD8 Ab had been administered before tumor challenge evidenced dramatically decreased survival rates (Fig.  6A ). The former case shows that protective antitumor immune response can be generated in mice lacking CD8 ϩ T cells at the time of immunization. However, as the results in the latter case suggested two possibilities-that either CD8 ϩ T cells are one of the primary effector cells for tumor rejection, or that CD8 ϩ DC is required for tumor rejection during the adaptive phase of the immune response-we transferred purified CD8 ϩ DC to the anti-CD8 
Ab-treated immune WT and MHCI
Ϫ/Ϫ mice immediately before the tumor challenge. In the WT mice, the transferred DC were not able to restore protective immunity, thus demonstrating that the CD8 ϩ T cells become the principal antitumor effector cells when they are present at the time of immunization. MHCI Ϫ/Ϫ mice, however, evidenced superior survival against anti-CD8 Ab treatment, as compared with the WT mice. Moreover, survival in these mice was restored completely by virtue of the transfer of the CD8 ϩ DCs (Fig. 6B) . These results indicate that the CD4 ϩ T cells become the primary antitumor effector cells when CD8 ϩ T cells are absent at the time of immunization, and that CD8
ϩ DCs substantially augment the protective activity of tumor-specific CD4 ϩ T cells.
Discussion
NKT cells appear to initiate a rapid protective immune response against infection via the modulation of adaptive immune responses against pathogens (2, 10, 32) . Although the results of a recent study showed clearly that a minor subpopulation of NKT cells can down-regulate tumor immunosurveillance (33), ␣-GalCer, an NKT cell ligand, is a promising immunomodulatory agent, which is currently being evaluated for its possible benefits in antitumor therapy (2, 17, 25, 34) . The in vivo stimulation of NKT cells with ␣-GalCer has been shown to modulate acquired protective immunity. Gonzalez-Aseguinolaza et al. (15) reported that ␣-GalCer administered to mice immunized with malaria Ag augmented protective antimalaria immunity. Thus far, however, it remains unclear as to the manner in which ␣-GalCer, as an adjuvant, modulates acquired antitumor immunity. We determined that the coadministration of ␣-GalCer and tumor Ag successfully induced protective antitumor immune responses during the adaptive phase. Furthermore, the acquired antitumor immunity was maintained for as long as 150 days, thereby indicating that long-term memory was elicited by vaccination with ␣-GalCer. The increase of the CD44 high memory type marker in CD8 ϩ and CD4 ϩ T cells supports the notion of this long-term memory antitumor effect (data not shown). During the time in which our manuscript was being prepared, Liu et al. (28) also reported the establishment of NKT cell-dependent adaptive immune responses against tumor Ags. In this report, they demonstrated that CD8 ϩ T cells are direct antitumor effect cells, although both CD4 ϩ and CD8 ϩ T cells appear to be required for tumor rejection. Nishimura et al. (35) also showed the induction of CTL against MBL-2 tumors upon immunization in the context of ␣-GalCer.
In our study, the ␣-GalCer-based vaccine model clearly illustrates the pivotal role of tumor-specific CD4
ϩ T cells and IFN-␥-secreting NK cells during tumor eradication. The coadministration of ␣-GalCer and tumor Ags resulted in an increase in the number of IFN-␥-secreting CD4 ϩ T cells and NK cells after a live-tumor cell challenge, by ϳ10-and 4-fold on day 4, respectively. Although CD8 ϩ T cells may play crucial roles in antitumor immunity ( Fig. 2A) , we determined that CD8 ϩ T cells were dispensable. CD4
ϩ T cells and NK cells, however, were found to elicit the antitumor response, and were essential for tumor rejection in cases in which ␣-GalCer was used as an adjuvant. This may be the consequence of FasL expression by B16, which has been determined to protect the tumor from direct CTL-mediated killing (36) . However, our data appear consistent with the findings of previous adoptive transfer experiments, in which it was shown that the transfer of CD4 ϩ T cell clones inhibited the growth of tumor cells which do not express MHC class II themselves without completely eliminating the tumor cells, and that the transfer of positively selected CD4 ϩ T cells or CD8-depleted lymph node cells obtained from immunized mice resulted in tumor rejection in SCID mice (37) .
This observation mandates the existence of a CD4 ϩ T cell-dependent effector mechanism aside from the MHC class I-restricted CD8 ϩ CTL. The weak involvement of CD8 ϩ CTL in tumor rejection and the observed augmented protection of CTL-deficient mice (MHCI Ϫ/Ϫ ) in the ␣-GalCer/tumor extract immunized model raised the possibility that the activation of NKT cells may, in turn, elicit the activation of both antitumor CD8
ϩ CTLs and suppressive CD8 ϩ T cells, which can down-regulate the activity of antitumor CD4 ϩ T cells. Thus, CD8 ϩ T cell-deficient animals establish strong antitumor CD4 ϩ T cell responses with the assistance of NKT cells. However, in WT mice, antitumor CD4 ϩ and CD8 ϩ T cell responses may be accompanied by the activation of suppressive CD8 ϩ T cell responses. We verified this possibility via the elimination of CD8 ϩ T cells either before or after immunization using anti-CD8 mAb. When anti-CD8 mAb was injected, before immunization, the mice retained their tumor-rejection capacity. However, the administration of anti-CD8 mAb after immunization resulted in the abrogation of tumor-rejection capacity in the immunized mice. These results show that the subpopulation of suppressor CD8 ϩ T cells generated by the activated NKT cells can down-regulate, to a certain degree, tumor-specific CD4 ϩ T cell response (S. Hong and S.-H. Park, manuscript in preparation). Another possibility is that the MHC class I molecules may function as inhibitory molecules for NKT cells, as has been reported by Ikarashi et al. (38) . Thus, in MHCI Ϫ/Ϫ mice, NKT cells are more profoundly activated by ␣-GalCer than is observed in WT mice. Lastly, activated CD8 ϩ T cells may kill off APCs with cross-presenting tumor Ag, thus inhibiting the optimal priming or boosting of CD4 ϩ T cells which require serial contacts with APC for expansion.
Treatment with ␣-GalCer appears to give rise to the activation of NK cells, B cells, and DCs, ultimately resulting in a selective proliferation of memory CD4 ϩ and CD8 ϩ T cells via NKT activation (12, 14, 39) , and in the secretion of IFN-␥ by NK cells (40, 41) . IFN-␥ is the principal cytokine mediating the effects of ␣-GalCer during the innate phase and tumor rejection in most tumor models (42, 43) . IFN-␥ has also been shown to compel monocytes, macrophages, fibroblasts, and certain tumor cells to generate monokine induced by IFN-␥, IFN-inducible protein 10, and CXC chemokines (44 -46) . These substances exert powerful antiangiogenic effects by damaging the tumor vasculature, resulting in both the inhibition of growth and tumor necrosis (47) . Our finding that protective antitumor immune response is abrogated in mice lacking IFN-␥ shows that IFN-␥ is of central importance in the mediation of the adjuvant effects of ␣-GalCer. This is also consistent with the possibility that NK and CD4 ϩ T cell-derived IFN-␥ causes macrophages to secrete antitumor factors. Indeed, we determined that the ␣-GalCer-vaccinated mice all exhibited elevated IFN-␥ levels, coupled with an increased quantity of CD11c ϩ cells and CD11b int granulocytes. A recent study asserted that granulocytes appear to play a role in tumor regression (48) , whereas macrophages appear to participate in the antitumor activity of Agspecific CD4 ϩ T cells (29, 49) . Thus, it seems conceivable that tumor stromal monocytes and macrophages are key effector cells that mediate IFN-␥ antitumor activity. Although the results of our study allowed us to conclude that IFN-␥ is required by CD4 ϩ T cells for complete tumor cell elimination, the possibility cannot be excluded that other cytokines secreted by Ag-stimulated immune cells may have also participated and synergized with IFN-␥, affecting the release of IFN-inducible protein 10 and monokine induced by IFN-␥, and/or the activation of other tumoricidal cells. Our observation that mice lacking IL-4 or IL-12␤ did not reject the tumor transplants, yet evidenced a modest increase in survival rates, is consistent with this notion. These data are, again, concordant with previous studies, in which NKT activation and CD4 ϩ T cells were required for the promotion of IFN-␥ production by CD4 ϩ T cells and NK cells (29, 37, 40) . We propose that the IFN-␥ generated by memory CD4 ϩ T cells generates an early cytokine environment, allowing for the activation of NK cells and the recruitment of APCs.
Another interesting observation of this study was that the adjuvant potency of ␣-GalCer was independent of the tumor model (solid and metastasis) or tumor cell line used. We determined that vaccination with ␣-GalCer inhibited tumor growth in both the solid tumor model (after s.c. injection) and the lung metastasis model (after i.v. injection), thereby indicating that ␣-GalCer-induced protective immunity is not restricted to certain tumor injection sites, but is systemically effective. This further illustrates that tumor rejection is mediated not by the NKT cells themselves, but rather by immunized adaptive immune cells. Broad protection effects were observed not only with melanoma cells (B16, B6 originated), but also with different tumor cell lines, including lymphoma (EL-4 originated on B6), sarcoma (MB19 originated on B6), and carcinoma (26-M3.1 originated on BALB/c) cell lines. The adjuvant effects of ␣-GalCer were much more potent than those of CFA, a representative adjuvant. In animal studies, tumors modified to secrete IFN-␥ (50) or to express B7.1 (51) are often rejected, and these systems tend to generate systemic immunity against WT tumor challenges. In other studies, the cotransfection of the B7 molecule with MHC class II molecules is required for the induction of potent systemic immunity (52) . Our vaccination system, however, achieved equal or superior antitumor effects, without the need for artificial genetic modifications such as the transfection of the B7 molecule or IFN-␥. In this regard, the results of this study suggest that the activation of NKT cells, using the ␣-GalCer ligand, constitutes a simple and powerful method for the induction of a potent antitumor adaptive immune response against a variety of tumor models and tumor cell lines.
This study is, to our knowledge, the first report regarding the pivotal role of NKT cells in the establishment of an Ag-specific CD4 ϩ T cell-mediated adaptive immune response and in the assistance of the T cell-mediated regulation of the adaptive immune response. It appears likely that an identical antitumor mechanism is operational in the human immune system, in which the CD1d/ NKT pathways are quite well-conserved (53). This, if it is the case, may facilitate the design of more effective vaccines against other intracellular pathogens, in addition to tumors.
